Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to Hold at StockNews.com

StockNews.com cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a hold rating in a research report released on Friday morning.

ALNY has been the subject of several other reports. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Morgan Stanley increased their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Scotiabank decreased their target price on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research report on Friday, February 14th. Finally, HC Wainwright raised their target price on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a report on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $310.22.

Alnylam Pharmaceuticals Trading Up 11.8 %

Shares of ALNY opened at $283.34 on Friday. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39. The firm has a market capitalization of $36.68 billion, a P/E ratio of -130.57 and a beta of 0.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock’s fifty day simple moving average is $257.16 and its 200 day simple moving average is $259.74.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities research analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds have recently made changes to their positions in ALNY. Larson Financial Group LLC increased its position in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares during the period. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $28,000. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $33,000. Colonial Trust Co SC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $35,000. Finally, True Wealth Design LLC grew its position in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.